Publications by authors named "Andaç Salman"

44 Publications

Public interest in dermatologic symptoms, conditions, treatments, and procedures during the COVID-19 pandemic: Insights from Google Trends.

Dermatol Ther 2021 Mar 25;34(2):e14895. Epub 2021 Feb 25.

Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.

Coronavirus disease 2019 (COVID-19) pandemic had substantial effect both on daily life and medical practice. Internet data have been used to analyze the trends in public interest in various medical conditions and treatments. The aim of this study is to analyze the public interest in dermatologic symptoms, conditions, treatments, and procedures during the COVID-19 pandemic. Google Trends was queried for a total of 120 dermatological search queries. Three periods of 2020 ([March 15-May 9], [May 10-July 4], and [July 5-October 31]) were compared with the previous 4 years (2016-2019). A significantly decreased interest in skin cancers and certain dermatologic conditions (eg, pityriasis rosea and scabies) was observed throughout the study period. Whereas a significant increase of interest in dry skin, hair shedding, oily hair, atopic dermatitis, and hand eczema was detected during the study. An initial decrease in interest was followed by a significant increase for acne, comedones, melasma, rosacea, botox, dermaroller, and peeling. The study demonstrated a significant impact of the COVID-19 pandemic on the public interest in dermatology. The present results would help to create healthcare policies and information sources, which can meet the public demand. The reasons for the observed trends and their effect on patient outcomes might be of interest for future studies.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.14895DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995005PMC
March 2021

A case series and literature review of erythema palmare hereditarium (Lane's disease).

Indian J Dermatol Venereol Leprol 2021 Jan-Feb;87(1):64-66

Department of Dermatology, School of Medicine, Marmara University, Istanbul, Turkey.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.25259/IJDVL_112_20DOI Listing
February 2020

The global impact of the COVID-19 pandemic on the management and course of chronic urticaria.

Authors:
Emek Kocatürk Andaç Salman Ivan Cherrez-Ojeda Paulo Ricardo Criado Jonny Peter Elif Comert-Ozer Mohamed Abuzakouk Rosana Câmara Agondi Mona Al-Ahmad Sabine Altrichter Rand Arnaout Luisa Karla Arruda Riccardo Asero Andrea Bauer Moshe Ben-Shoshan Jonathan A Bernstein Mojca Bizjak Isabelle Boccon-Gibod Hanna Bonnekoh Laurence Bouillet Zenon Brzoza Paula Busse Regis A Campos Emily Carne Niall Conlon Roberta F Criado Eduardo M de Souza Lima Semra Demir Joachim Dissemond Sibel Doğan Günaydın Irina Dorofeeva Luis Felipe Ensina Ragıp Ertaş Silvia Mariel Ferrucci Ignasi Figueras-Nart Daria Fomina Sylvie M Franken Atsushi Fukunaga Ana M Giménez-Arnau Kiran Godse Margarida Gonçalo Maia Gotua Clive Grattan Carole Guillet Naoko Inomata Thilo Jakob Gul Karakaya Alicja Kasperska-Zając Constance H Katelaris Mitja Košnik Dorota Krasowska Kanokvalai Kulthanan M Sendhil Kumaran Claudia Lang José Ignacio Larco-Sousa Elisavet Lazaridou Tabi Anika Leslie Undine Lippert Oscar Calderón Llosa Michael Makris Alexander Marsland Iris V Medina Raisa Meshkova Esther Bastos Palitot Claudio A S Parisi Julia Pickert German D Ramon Mónica Rodríguez-Gonzalez Nelson Rosario Michael Rudenko Krzysztof Rutkowski Jorge Sánchez Sibylle Schliemann Bulent Enis Sekerel Faradiba S Serpa Esther Serra-Baldrich Zhiqiang Song Angèle Soria Maria Staevska Petra Staubach Anna Tagka Shunsuke Takahagi Simon Francis Thomsen Regina Treudler Zahava Vadasz Solange Oliveira Rodrigues Valle Martijn B A Van Doorn Christian Vestergaard Nicola Wagner Dahu Wang Liangchun Wang Bettina Wedi Paraskevi Xepapadaki Esra Yücel Anna Zalewska-Janowska Zuotao Zhao Torsten Zuberbier Marcus Maurer

Allergy 2021 03 29;76(3):816-830. Epub 2020 Dec 29.

Urticaria Center of Reference and Excellence (UCARE), Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin, Berlin, Germany.

Introduction: The COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown.

Aim: To understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19.

Materials And Methods: Our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences.

Results: The COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19.

Conclusions: The COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/all.14687DOI Listing
March 2021

Yellow Urticaria.

J Allergy Clin Immunol Pract 2021 Jan 3;9(1):479-480. Epub 2020 Nov 3.

Marmara University School of Medicine, Department of Dermatology, Istanbul, Turkey.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2020.10.029DOI Listing
January 2021

Comment on "Cling film for mobile phones to prevent cross-infection during the COVID-19 pandemic".

J Am Acad Dermatol 2021 01 1;84(1):e35-e36. Epub 2020 Oct 1.

Department of Dermatology, Anadolu Medical Center, Kocaeli, Turkey.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.09.073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527834PMC
January 2021

Netherton syndrome: Temporary response to dupilumab.

Pediatr Dermatol 2020 Nov 19;37(6):1210-1211. Epub 2020 Sep 19.

Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.

Netherton syndrome (NS) is an orphan disease characterized by congenital ichthyosis, hair abnormalities, and atopy, with limited treatment options. We achieved temporary improvement only during the initial 6 weeks of treatment with dupilumab, which differs from the sustained improvement observed in 2 other recently published cases. Although the clinical presentation of atopy and increased pre-allergic cytokines in NS patients suggest that dupilumab may be beneficial, larger studies are required.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.14362DOI Listing
November 2020

Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress.

Drugs 2020 Nov;80(16):1617-1634

Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.

Chronic spontaneous urticaria (CSU) is characterized by the presence of wheals, angioedema, or both for at least 6 weeks. It may persist for a long time-up to 50% of the patients have been reported to be symptomatic 5 years after the onset. Some patients can suffer more than one episode of CSU during their lifetime. Considering the recurrences, disabling symptoms, and significant impact on quality of life, proper and effective treatment of CSU is critical. The use of antihistamines (AHs) is still the mainstay of treatment. However, given the low rates of response to AHs (38.6% and 63.2% to standard doses and higher doses, respectively), the complete control of symptoms seems difficult to attain. The use of omalizumab for CSU has been a major breakthrough in the care of patients with CSU. However, the partial response and lack of response to omalizumab in a subgroup of patients, as high as 70% in some studies, make the development of alternative treatments desirable. Ever-increasing knowledge on the pathogenesis is making new target molecules available and enabling drug development for CSU. In addition to drug repurposing as in anti-IL-4/13, IL-5, and IL-17 antibodies, novel targeted therapy options such as ligelizumab and Bruton's tyrosine kinase inhibitors are currently undergoing clinical trials and will be available in the near future. This article reviews the current challenges in the treatment of CSU, the pathogenesis and potential target molecules, and the rationale for novel treatments and their rapidly developing status.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-020-01387-9DOI Listing
November 2020

Visual Dermatology: Koebner's Phenomenon Due to Wet Cupping Therapy.

J Cutan Med Surg 2020 Jun 29:1203475420936654. Epub 2020 Jun 29.

Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420936654DOI Listing
June 2020

Definition, aims, and implementation of GA LEN/HAEi Angioedema Centers of Reference and Excellence.

Authors:
Marcus Maurer Werner Aberer Rosana Agondi Mona Al-Ahmad Maryam Ali Al-Nesf Ignacio Ansotegui Rand Arnaout Luisa Karla Arruda Riccardo Asero Emel Aygören-Pürsün Aleena Banerji Andrea Bauer Moshe Ben-Shoshan Alejandro Berardi Jonathan A Bernstein Stephen Betschel Carsten Bindslev-Jensen Mojca Bizjak Isabelle Boccon-Gibod Konrad Bork Laurence Bouillet Henrik Balle Boysen Nicholas Brodszki Sigurd Broesby-Olsen Paula Busse Thomas Buttgereit Anette Bygum Teresa Caballero Régis A Campos Mauro Cancian Ivan Cherrez-Ojeda Danny M Cohn Célia Costa Timothy Craig Paulo Ricardo Criado Roberta F Criado Dorottya Csuka Joachim Dissemond Aurélie Du-Thanh Luis Felipe Ensina Ragıp Ertaş José E Fabiani Claudio Fantini Henriette Farkas Silvia Mariel Ferrucci Ignasi Figueras-Nart Natalia L Fili Daria Fomina Atsushi Fukunaga Asli Gelincik Ana Giménez-Arnau Kiran Godse Mark Gompels Margarida Gonçalo Maia Gotua Richard Gower Anete S Grumach Guillermo Guidos-Fogelbach Michihiro Hide Natalia Ilina Naoko Inomata Thilo Jakob Dario O Josviack Hye-Ryun Kang Allen Kaplan Alicja Kasperska-Zając Constance Katelaris Aharon Kessel Andreas Kleinheinz Emek Kocatürk Mitja Košnik Dorota Krasowska Kanokvalai Kulthanan M Sendhil Kumaran José Ignacio Larco Sousa Hilary J Longhurst William Lumry Andrew MacGinnitie Markus Magerl Michael P Makris Alejandro Malbrán Alexander Marsland Inmaculada Martinez-Saguer Iris V Medina Raisa Meshkova Martin Metz Iman Nasr Jan Nicolay Chikako Nishigori Isao Ohsawa Kemal Özyurt Nikolaos G Papadopoulos Claudio A S Parisi Jonathan Grant Peter Wolfgang Pfützner Todor Popov Nieves Prior German D Ramon Adam Reich Avner Reshef Marc A Riedl Bruce Ritchie Heike Röckmann-Helmbach Michael Rudenko Andaç Salman Mario Sanchez-Borges Peter Schmid-Grendelmeier Faradiba S Serpa Esther Serra-Baldrich Farrukh R Sheikh William Smith Angèle Soria Petra Staubach Urs C Steiner Marcin Stobiecki Gordon Sussman Anna Tagka Simon Francis Thomsen Regina Treudler Solange Valle Martijn van Doorn Lilian Varga Daniel O Vázquez Nicola Wagner Liangchun Wang Christina Weber-Chrysochoou Young-Min Ye Anna Zalewska-Janowska Andrea Zanichelli Zuotao Zhao Yuxiang Zhi Torsten Zuberbier Ricardo D Zwiener Anthony Castaldo

Allergy 2020 08 27;75(8):2115-2123. Epub 2020 Apr 27.

HAE International (HAEi), Fairfax City, VA, USA.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/all.14293DOI Listing
August 2020

Advanced Glycation End Products, a Potential Link between Psoriasis and Cardiovascular Disease: A Case-control Study.

Indian J Dermatol 2019 May-Jun;64(3):201-206

Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey.

Context: Advanced glycation end products (AGEs) promote oxidative stress and inflammation by altering structure and function of proteins. They are excessively produced mainly in hyperglycemia, chronic inflammation and are involved in the development of atherosclerosis and cardiovascular disease.

Aims: The aim of this study was to investigate whether skin AGEs levels were increased and had relation to premature atherosclerosis in patients with psoriasis.

Subjects And Methods: Fifty-two psoriasis patients and 20 healthy controls (HC) were included. AGEs were determined by skin autofluorescence (SAF) analysis. High-sensitive C-reactive protein (hsCRP) and carotid intima-media thickness (CIMT) were also investigated. Physical activity and dietary patterns were determined.

Statistical Analysis Used: Fisher's exact test, two-sample -tests, Mann-Whitney-U test, Pearson correlation, Spearman correlation, and Wilcoxon test.

Results: SAFs were increased in psoriasis patients (1.8 arbitrary units [AUs]) compared to that in HC (1.6 AUs) ( = 0.057). Median CIMT values of HC and psoriasis groups were 0.43 (0.28-0.79), and 0.59 (0.44-0.98) respectively and the differences were significant ( = 0.001); hsCRP levels were not different between groups.

Conclusions: Skin AGE accumulation was found to have a correlation with CIMT in psoriasis patients providing evidence for the role of AGEs in premature atherosclerosis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijd.IJD_396_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537697PMC
June 2019

The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.

Dermatol Ther 2019 07 25;32(4):e12975. Epub 2019 Jun 25.

Department of Biostatistics, Marmara University School of Medicine, Istanbul, Turkey.

Background: Omalizumab is a third-line treatment for chronic spontaneous urticaria (CSU). However, the real-life data on the impact of omalizumab on CSU-related quality of life (QoL) remain scarce.

Objectives: To investigate the impact of omalizumab on QoL and its predictors in CSU. A retrospective cohort study was done. The response to therapy was evaluated using urticaria activity score over 7 days (UAS7) and urticaria control test (UCT); the impairment in QoL was assessed using dermatology life quality index (DLQI) and chronic urticaria quality of life questionnaire (CU-Q2oL).

Results: Forty-two patients were included. All scores improved from baseline to first month and remained stable at the third month of treatment (p < .001). The gender, age, and angioedema had no significant effect on QoL, but the complete responders (UAS7:0-1) had better improvement rates in all scores compared to others. The baseline UAS7, DLQI, and CU-Q2oL scores were lower at the baseline in complete responders (p = .0001).

Conclusions: A rapid and continual improvement in QoL was obtained with omalizumab treatment. A better UAS7, UCT, DLQI, and CU-Q2oL score at the baseline might be a predictor of a better response to omalizumab and more improvement in QoL.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12975DOI Listing
July 2019

Acute generalized exanthematous pustulosis due to ceftriaxone: Report of a pediatric case with recurrence after positive patch test.

Pediatr Dermatol 2019 Jul 3;36(4):514-516. Epub 2019 May 3.

Division of Pediatric Infectious Diseases, Marmara University School of Medicine, Istanbul, Turkey.

Acute generalized exanthematous pustulosis (AGEP) is seen uncommonly in children and sometimes shows atypical clinical features in this population. Patch testing can be used effectively in children for the confirmation of the culprit drug in cases of multiple drug use. Here, we report a rare, pediatric case of ceftriaxone-induced AGEP confirmed by patch testing with subsequent recurrence of the skin eruption.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.13838DOI Listing
July 2019

The Real-Life Effectiveness and Safety of Omalizumab Updosing in Patients With Chronic Spontaneous Urticaria.

J Cutan Med Surg 2019 Sep/Oct;23(5):496-500. Epub 2019 Apr 29.

1 Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.

Background: Omalizumab is a third-line treatment for chronic spontaneous urticaria (CSU). Studies investigating the use of higher doses of omalizumab in patients unresponsive to regular doses are limited.

Objectives: This study aims to investigate the effectiveness and safety of omalizumab 450 mg in CSU.

Methods: A retrospective cohort study was conducted. The response to therapy was evaluated using the Urticaria Activity Score over 7 days (UAS7) and the Urticaria Control Test (UCT). Patients showing complete response (CR) (UAS7: 0-1) to omalizumab 300 mg (Group 1) and patients receiving at least 3 doses of omalizumab 450 mg (Group 2) between 2016 and 2018 were included.

Results: A total of 72 patients (Group 1: 59; Group 2: 13) were included. In Group 2, the mean UAS7 score decreased from 18.6 to 5.1 and the mean UCT score increased from 8.6 to 12 after a mean 4.3 courses of 450 mg omalizumab treatment. Of the 13 patients in Group 2, 6 had CR and 3 had good disease control (UAS7: 2-6). The rate of patients with low baseline IgE levels (< 43 IU/mL) was significantly higher in Group 2.

Conclusions: Higher doses of omalizumab are effective and safe in patients with CSU that is unresponsive to omalizumab 300 mg. Lower baseline total IgE levels might be used as a predictor of nonresponse to omalizumab and the need for higher doses.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475419847956DOI Listing
February 2020

The efficacy and safety of targeted narrowband UVB therapy: a retrospective cohort study

Turk J Med Sci 2019 Apr 18;49(2):595-603. Epub 2019 Apr 18.

Background/aim: Phototherapy is a safe and effective treatment modality for numerous dermatological conditions. Recently, targeted phototherapy modalities have gained importance due to their advantages over conventional phototherapy.This retrospective study aimed to evaluate the safety and efficacy of targeted narrowband UVB phototherapy in patients with dermatological disorders

Materials And Methods: This single-center study included 173 patients who were treated with targeted narrowband UVB phototherapy. Demographic features, phototherapy parameters, and adverse effects were evaluated in all patients, and the treatment response was assessed in patients who attended at least one follow-up visit.

Results: A total of 173 patients (102 females; 71 males) with vitiligo, alopecia areata, lichen simplex chronicus, palmoplantar psoriasis, and psoriasis vulgaris were included in the study. Among 73 patients, with whom the treatment was finalized by physician, an excellent response was obtained in 10%, 52.9%, 53.8%, 28.6%, and 40% of patients with vitiligo, alopecia areata, lichen simplex chronicus, palmoplantar psoriasis, and psoriasis, respectively. The treatment was generally well tolerated and was discontinued in only two patients due to adverse effects.

Conclusion: This study demonstrates that targeted narrowband UVB therapy is a safe and effective treatment alternative, particularly for alopecia areata, lichen simplex chronicus, and palmoplantar and plaque-type psoriasis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3906/sag-1810-110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018302PMC
April 2019

Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.

J Dermatolog Treat 2020 Mar 7;31(2):204-209. Epub 2019 Mar 7.

Department of Dermatology, Hospital del Mar, IMIM, Universitat Autònoma, Barcelona, Spain.

The real-life data on the effectiveness and safety of omalizumab in chronic spontaneous urticaria (CSU) with validated methods are scarce. There is also a lack of information on the use of combination treatments. A retrospective cohort study was done to evaluate the effectiveness and safety of omalizumab in real-life conditions. The patients with CSU treated with omalizumab between 2015 and 2018 were included. The response to therapy was evaluated using urticaria activity score over 7 days (UAS7) and urticaria control test (UCT). A total of 106 patients were included. A complete response (CR) (UAS7:0) and a well-controlled activity (WCA) (UAS7:1 to <6) were observed in 50 (47.2%) and 35 (33%) patients, respectively. The number of patients with an UCT score ≥12 was also significantly increased. Higher rates of CR/WCA were observed with omalizumab monotherapy compared to combination with antihistamines. The combination of dapsone, colchicine, and omalizumab provided additional benefit in a small group. Treatment with omalizumab provided a rapid and sustainable improvement in real-life settings. The use of omalizumab as monotherapy or combined with antihistamines does not show differences in the treatment response. The combination of omalizumab with immunomodulatory agents might be of benefit in selected cases.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1589639DOI Listing
March 2020

"Slime": A trending cause of isothiazolinone contact allergy in children.

Contact Dermatitis 2019 Jun 15;80(6):409-411. Epub 2019 Mar 15.

Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/cod.13237DOI Listing
June 2019

Margin-Controlled, Staged Surgical Excision in the Treatment of High-Risk Basal Cell Carcinomas of the Head and Neck Region.

J Cutan Med Surg 2019 May/Jun;23(3):258-264. Epub 2018 Dec 17.

2 Department of Plastic Reconstructive and Aesthetic Surgery, Marmara University School of Medicine, Istanbul, Turkey.

Background: The most common skin cancer is basal cell carcinoma (BCC), and the gold-standard treatment for high-risk tumours is Mohs surgery. However, alternative methods are needed for high-risk tumours in countries where the performance rate of Mohs surgery is low.

Objectives: The objective of this article is to investigate the feasibility, efficacy, and safety of margin-controlled, staged surgical excision (MCSSE) in high-risk tumours as a possible treatment alternative.

Methods: A retrospective cohort study, including patients diagnosed with high-risk BCC in the head and neck region and treated with MCSSE between 2003 and 2010, was conducted.

Results: During the study period 50 tumours in 47 patients were treated, with low adverse event rates and high patient satisfaction rates. Of the 50 tumours, 1 recurred at the 12-month follow-up.

Conclusions: Despite the small sample size and relatively short follow-up period, the present study shows that MCSSE might be a feasible alternative for the treatment of high-risk BCCs in institutions where Mohs surgery is not performed. Future studies on long-term recurrence rates are needed.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475418820868DOI Listing
December 2019

Impact of psoriasis in the quality of life of children, adolescents and their families: a cross-sectional study.

An Bras Dermatol 2018 Nov/Dec;93(6):819-823

Department of Child and Adolescent Psychiatry, Marmara University School of Medicine, Pendik Research and Training Hospital, Istanbul, Turkey.

Background: Psoriasis is a chronic and inflammatory disease that impairs quality of life and causes psychological symptoms. Despite the high prevalence of psoriasis in pediatric patients, studies investigating the impact of psoriasis in the quality of life of children, adolescents and families are sparse.

Objective: To investigate the impact of psoriasis in the quality of life of children and adolescents with psoriasis and their families and to determine depression and anxiety levels of the patients.

Methods: A total of 58 patients with psoriasis aged 7-18 years (median age: 11) and a family member of each patient were included in the study. Children's Dermatology Life Quality Index (CDLQI), Family Dermatology Life Quality Index (FDLQI), Children's Depression Inventory (CDI) and State-Trait Anxiety Inventory for Children (STAIC) were used in the study.

Results: The median PASI score of the patients included in the study was 1.8. The median CDLQI and FDLQI scores in the study groups were 5 and 10, respectively. The median CDI score, STAIC-state and STAIC-trait scores of the patients were 6, 28 and 32.5, respectively.

Study Limitations: Lack of a control group and patient assessment of disease severity. Relatively mild disease severity of the subjects.

Conclusions: Psoriasis has a negative impact in the quality of life of children, adolescents and their families, even in the presence of mild disease. Considering that impairment in quality of life may be associated with psychosocial morbidity, a combined approach with medical therapy, family counseling and quality of life assessment may be beneficial in this patient group.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1590/abd1806-4841.20186981DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256235PMC
February 2019

Methylchloroisothiazolinone and methylisothiazolinone contact allergy: A retrospective cohort study from a tertiary dermatology clinic in Turkey.

Authors:
Andac Salman

Contact Dermatitis 2019 Mar 13;80(3):193-194. Epub 2018 Dec 13.

Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/cod.13175DOI Listing
March 2019

Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.

Dermatol Online J 2017 Jul 15;23(7). Epub 2017 Jul 15.

Marmara University School of Medicine, Department of Dermatology, Istanbul, Turkey.

Janus kinase inhibitors are emerging treatment alternatives in various immune-mediated diseases including alopecia universalis. Herein, we report a patient with psoriasis and alopecia universalis in whom treatment with tofacitinib led to remission of psoriasis without improvement in alopecia universalis. Despite the promising potential in alopecia areata treatment, research evaluating the efficacy of different Janus kinase inhibitors and possible prognostic factors related with a more favorable response are warranted.
View Article and Find Full Text PDF

Download full-text PDF

Source
July 2017

Mesalazine-induced bullous fixed drug eruption.

Contact Dermatitis 2018 Jul 15;79(1):34-35. Epub 2018 Feb 15.

Department of Dermatology, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/cod.12972DOI Listing
July 2018

Impact of psoriasis in the quality of life of children, adolescents and their families: a cross-sectional study.

An Bras Dermatol 2018 Nov - Dec;93(6):819-823

Department of Child and Adolescent Psychiatry, Marmara University School of Medicine, Pendik Research and Training Hospital, Istanbul, Turkey.

Background: Psoriasis is a chronic and inflammatory disease that impairs quality of life and causes psychological symptoms. Despite the high prevalence of psoriasis in pediatric patients, studies investigating the impact of psoriasis in the quality of life of children, adolescents and families are sparse.

Objective: To investigate the impact of psoriasis in the quality of life of children and adolescents with psoriasis and their families and to determine depression and anxiety levels of the patients.

Methods: A total of 58 patients with psoriasis aged 7-18 years (median age: 11) and a family member of each patient were included in the study. Children's Dermatology Life Quality Index (CDLQI), Family Dermatology Life Quality Index (FDLQI), Children's Depression Inventory (CDI) and State-Trait Anxiety Inventory for Children (STAIC) were used in the study.

Results: The median PASI score of the patients included in the study was 1.8. The median CDLQI and FDLQI scores in the study groups were 5 and 10, respectively. The median CDI score, STAIC-state and STAIC-trait scores of the patients were 6, 28 and 32.5, respectively.

Study Limitations: Lack of a control group and patient assessment of disease severity. Relatively mild disease severity of the subjects.

Conclusions: Psoriasis has a negative impact in the quality of life of children, adolescents and their families, even in the presence of mild disease. Considering that impairment in quality of life may be associated with psychosocial morbidity, a combined approach with medical therapy, family counseling and quality of life assessment may be beneficial in this patient group.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1590/abd1806-4841.20186981DOI Listing
January 2017

Acquired progressive lymphangioma: Case report with partial response to imiquimod 5% cream.

Pediatr Dermatol 2017 Nov 21;34(6):e302-e304. Epub 2017 Sep 21.

Department of Dermatology, School of Medicine, Marmara University, Istanbul, Turkey.

Acquired progressive lymphangioma (APL), or benign lymphangioendothelioma, is an unusual entity derived from vascular structures. Clinically and histopathologically it may resemble Kaposi's sarcoma and well-differentiated angiosarcoma, causing a diagnostic problem. We report an individual with APL initially diagnosed with Kaposi's sarcoma who underwent unnecessary laboratory testing. Imiquimod 5% cream stopped the progression of the lesion. Awareness of this rare entity may prevent patients from undergoing excessive testing. Imiquimod may be used as a safe, effective treatment option.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.13283DOI Listing
November 2017

Autoimmune Bullous Disease in Childhood.

Indian J Dermatol 2017 Jul-Aug;62(4):440

Department of Dermatology, School of Medicine, Marmara University, Istanbul, Turkey.

Background: Autoimmune bullous disorders (AIBDs) are a heterogeneous group of diseases which are rarely seen in children. Studies concerning the immunobullous diseases in pediatric patients are scarce.

Aims And Objectives: In this study, we aimed to investigate the clinical features and treatment outcomes of AIBDs in children.

Materials And Methods: The electronic records of the patients in our AIBDs outpatient clinic were retrospectively reviewed. All cases diagnosed before the age of 16 years were included in the analysis of clinical features, treatment outcomes, and follow-up data.

Results: Of the 196 patients with immunobullous diseases, 9 (4.6%) were diagnosed before the age of 16 years. Mean age of the patients at the time of diagnosis was 7.72 ± 5.66 years. Among nine patients, linear immunoglobulin A disease (LAD), pemphigus vulgaris (PV), and bullous pemphigoid (BP) were seen in 5, 2, and 2 children, respectively. All patients were treated with at least two systemic agents (including methylprednisolone, dapsone, methotrexate, salazopyrine, intravenous Ig [IVIg], and rituximab) leading to clinical remission in all of them after a mean period of 31.77 ± 27.99 months.

Conclusion: In line with earlier studies, LAD was the most common immunobullous disease and in general, associated with a favorable response to dapsone. This study was noteworthy in that the patients with PV and BP demonstrated a relatively more recalcitrant course, requiring rituximab and IVIg for remission, respectively. Overall, patients had a good prognosis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijd.IJD_366_16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527737PMC
August 2017

Hidradenitis suppurativa unresponsive to canakinumab treatment: A case report.

Indian J Dermatol Venereol Leprol 2017 Sep-Oct;83(5):615-617

Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijdvl.IJDVL_147_16DOI Listing
November 2018

Autoimmun-Progesteron-Dermatitis, die ein fixes Arzneimittelexanthem vortäuscht.

J Dtsch Dermatol Ges 2017 Feb;15(2):217-219

Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.12956_gDOI Listing
February 2017

Autoimmune progesterone dermatitis mimicking fixed drug eruption.

J Dtsch Dermatol Ges 2017 Feb 13;15(2):219-220. Epub 2017 Jan 13.

Marmara University School of Medicine, Department of Dermatology, Istanbul, Turkey.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.12956DOI Listing
February 2017

Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: A multicenter, cohort study.

J Dermatol 2017 Jun 10;44(6):630-634. Epub 2016 Dec 10.

Department of Public Health, Marmara University School of Medicine, Istanbul, Turkey.

The data on long-term efficacy, safety and drug survival rates of conventional systemic therapeutics in pediatric psoriasis is lacking. The primary aim of this study is to investigate acitretin, methotrexate, cyclosporin efficacy, safety and drug survival rates in pediatric patients as well as predictors of drug survival. This is a multicenter study including 289 pediatric cases being treated with acitretin, methotrexate and cyclosporin in four academic referral centers. Efficacy, adverse events, reasons for discontinuation, 1, 2- and 3-year drug survival rates, and determinants of drug survival were analyzed. A 75% reduction of Psoriasis Area and Severity Index score or better response rate was obtained in 47.5%, 34.1% and 40% of the patients who were treated with acitretin, methotrexate and cyclosporin, respectively. One-year drug survival rates for acitretin, methotrexate and cyclosporin were 36.3%, 21.1% and 15.1%, respectively. The most significant determinant of drug survival, which diminished over time, was treatment response whereas arthritis, body mass index and sex had no influence. Although all three medications are effective and relatively safe in children, drug survival rates are low due to safety concerns at this age group. Effective disease control through their rational use can be expected to improve survival rates.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.13713DOI Listing
June 2017

Neonatal lupus erythematosus: Report of a case with cutaneous, hematological and hepatobiliary findings.

Turk J Pediatr 2016 ;58(1):106-108

Marmara University School of Medicine Department of Dermatology, İstanbul, Turkey.

Neonatal lupus erythematosus is an autoimmune disorder mainly affecting the heart and skin. It is the most common cause of congenital heart block. In addition, hematological, hepatobiliary and neurological involvement may occur. Herein, we report a 23-day-old infant presented with annular, erythematous, and scaly and atrophic lesions on the face and trunk. Based on the clinical, laboratory and histopathological findings, she was diagnosed as neonatal lupus erythematosus. Neonatal lupus eryhtematosus should be considered in infants presenting with annular skin lesions, and we present this case to highlight the value of high index of clinical suspicion in diagnosis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.24953/turkjped.2016.01.017DOI Listing
June 2017

Infliximab-induced cutaneous eruption resembling pityriasis rubra pilaris in a patient with Takayasu's arteritis.

Dermatol Ther 2017 May 12;30(3). Epub 2016 Nov 12.

Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12443DOI Listing
May 2017